Publications by authors named "S Wasamoto"
Article Synopsis
- Pembrolizumab combined with platinum and pemetrexed (Pemb-Plt-PEM) is a promising first-line treatment for advanced non-squamous non-small-cell lung cancer (NSCLC), effective regardless of PD-L1 expression.
- A study assessed this treatment's safety and efficacy in elderly patients (75 years and older) who received Pemb-Plt-PEM in Japan, focusing on patient responses and adverse events.
- Results showed a 40% overall response rate and a median overall survival of 24 months, indicating that Pemb-Plt-PEM is both effective and feasible for treating non-squamous NSCLC in older patients.
Article Synopsis
- Pembrolizumab in combination with carboplatin and paclitaxel shows a 63.1% response rate in advanced non-small cell lung cancer, with median progression-free survival (PFS) of 7.3 months and overall survival (OS) of 16.5 months.
- Although several prognostic factors such as neutrophil-to-lymphocyte ratio (NLR) and Glasgow prognostic score (GPS) were evaluated, only the prognostic nutritional index (PNI) was significantly associated with overall survival, indicating that a PNI of 45 or higher correlates with better outcomes.
- The study concludes that while PNI is a useful predictor for overall survival in NSCLC patients undergoing Pemb-combination therapy
Background: Factors predicting the response to pembrolizumab plus platinum and pemetrexed combination therapy (Pemb-Plt-PEM) in nonsquamous non-small cell lung cancer (non-sq NSCLC) are unclear. We investigated the Glasgow Prognostic (GP) score, neutrophil-to-lymphocyte ratio (NLR), and body mass index (BMI) as predictors of response to initial treatment with combination therapy in individuals with advanced non-sq NSCLC.
Methods: We retrospectively reviewed 236 patients who received initial treatment with combination therapy for non-sq NSCLC at 13 institutions between December 2018 and December 2020.